埃达拉可以通过PI3K/AKT/NF-κB通路缓解BV-2微质介导的神经炎症
Li Yang1, Zhaoda Duan1,2, Dongyao Xu1
1School of basic medical science, Kunming Medical University, Kunming, 650500, China.
Advanced biology
|April 8, 2025
概括
埃达拉 (EDA) 可以通过减少神经炎症来治疗缺血性中风. 这项研究表明,EDA通过通过酸氨基醇3-酶/蛋白酶B (PI3K/Akt) 途径抑制微质激活而起作用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 缺血性中风 (IS) 是一个主要的健康问题.
- 微质 (MG) 介导的神经炎症在IS的发病过程中至关重要.
- 向MG激活为中风和神经退行性疾病提供了潜在的治疗策略.
研究的目的:
- 为了阐明埃达拉 (EDA) 在缺血性中风中的抗炎机制.
- 为了研究酸丁3-激酶/蛋白激酶B (PI3K/Akt) 信号通路在EDA对微质的影响中的作用.
主要方法:
- 网络药理学 (NP) 分析以确定潜在的途径.
- 在体外 (BV-2细胞中缺氧-葡萄糖) 和体内 (小鼠中脑动脉封闭) 缺血性中风模型.
- 西方斑点,免疫光染色,PI3K通路抑制剂 (LY294002) 和PI3K过度表达等离子体来分析分子变化.
主要成果:
- 网络药理学确定PI3K/Akt通路是微质中EDA的潜在目标.
- 在体外和体外模型中,EDA治疗调节了PI3K/Akt通路蛋白和炎症因子的酸化水平.
- 对PI3K路径的药理和遗传操纵证实了其参与EDA的抗炎作用.
结论:
- 埃达拉 (EDA) 通过调节PI3K/Akt信号通路,可以在缺血性中风中发挥其抗炎作用.
- 通过PI3K/Akt路径抑制微质激活是EDA治疗潜力的关键机制.
- 这些发现为EDA在缺血性中风的临床使用提供了机制基础,并表明了其他神经炎症疾病的潜力.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
196
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
196
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
144
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
144


